BXCL 702

Drug Profile

BXCL 702

Alternative Names: BXCL702

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inveni
  • Developer BioXcel Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Enzyme inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Diffuse large B cell lymphoma

Most Recent Events

  • 22 May 2018 Phase-I/II clinical trials in Acute myeloid leukaemia (IV) (BioXcel pipeline, May 2018)
  • 22 May 2018 Phase-I/II clinical trials in Diffuse large B cell lymphoma (IV) (BioXcel pipeline, May 2018)
  • 03 Nov 2017 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV) prior to 03/11/2017 (BioXcel pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top